Moreover, OS which combines GnRH antagonist co-treatment and GnRH-agonist (GnRHa) trigger has become a common tool aiming to eliminate severe early OHSS and to support the concept of an OHSS-free clinic [4, 5]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.